Medicine and artificial intelligence: a strategy for the future, employing Porter’s classic framework

Charlene JY Liew, MMed, FRCR

Correspondence: Dr Charlene Liew, Consultant, Department of Radiology, Changi General Hospital, 2 Simei Street 3, Singapore 529889. charlene_liew@cgh.com.sg

Singapore Med J 2019, 1–3
https://doi.org/10.11622/smedj.2019047
Published ahead of print: 14 June 2019

Online version can be found at
http://www.smj.org.sg/online-first
Dear Sir,

Medical doctors are not newcomers to the field of artificial intelligence (AI), with radiologists pioneering work in medical imaging perception in the 1980s. But as it stands today, radiology, and in fact the whole of healthcare, is a field ripe for disruption. In the past 5–10 years, there have been substantial new innovations in imaging from deep learning methods of image detection and classification. Current artificial neural networks have accuracy rates that surpass those of radiologists in narrow-based tasks such as nodule detection and pathologists in detecting lymph node metastasis from breast cancer, and that are likely close to parity with ophthalmologists for vision-threatening diabetic retinopathy, with an area under the curve of 0.958 (95% confidence interval 0.956–0.961). Natural language processing is also poised to transform the way electronic health records are utilised by clinicians and researchers.

In the late 1970s, Michael Porter described his classic framework and generic strategies for competitive advantage, which would go on to revolutionise the field of industrial strategy. The three generic strategies determining competitive advantage are cost reduction, differentiation and focus. How do we address these challenges using Porter’s strategies? Rather than focusing on a business, let us reframe the point of reference around healthcare as the organisation that requires a strategic rethink. Key to formulating a strategy is defining our capabilities and identifying competitive forces that pose a threat. We face competition from private healthcare contractors who may purchase AI technologies to market directly to patients, bypassing doctors entirely. We also face competition from equipment vendors who manufacture diagnostic devices such as computed tomography scanners or digital retinal cameras, aiming to integrate their business vertically in much the way Apple produces its phones by owning each part of the supply chain.
Our greatest strength lies, ironically, not in our ability to accurately detect and classify disease, but in our ability to tap on collective and individual experience to make clinical judgements based on data, and this is where we outshine diagnostic algorithms. This experience curve is not limited to knowledge gained from clinical practice but stems from many years of undergraduate basic medical science training beforehand. Currently, we differentiate ourselves by integrating multimodal streams of data from electronic health records and discussions with other colleagues from different specialties. This forms a very strong entry barrier.

That is not to say that AI technology should be resisted, such as by withholding domain expertise from software developers. On the contrary, our strategic goal should be to further differentiate ourselves by creating hybrid clinicians and AI as a form of collective intelligence. Indeed, it would be unethical, if not impossible, to stunt the progress of clinical medicine by blocking fundamental technology. It should also be noted that one of the modifiers of Porter’s competitive forces in industrial economics includes government policy, which is a very major consideration when studying the risks posed by new entrants to the market, but this is not addressed here for the sake of brevity.

Apart from thinking of ourselves as a product, we can also position ourselves as buyers to exert a strategic force upon the market and by backward integration: software is much easier to create than machines, and deep learning code is already freely available on an open source basis. Instead of buying expensive AI software, we have been creating our own, in-house.

In the future, a probable strategy is the diversification of medicine into a broader field that utilises all forms of data, including genomics, metadata, electronic health records and biometrics, to arrive at a timely diagnosis around the clock. Building an ecosystem to sustain this, together with other ‘information specialists’ such as pathologists, would create an even greater competitive advantage. Finally, using the time freed by increased productivity, ‘brand’ identification may be cultivated in our patients by increasing face-to-face interactions, doing
things ‘for’ rather than ‘to’ our patients and fostering awareness of our AI-enhanced capabilities that make medicine safer, more precise and more patient-focused, with the aim of establishing clinicians augmented with AI as the future gold standard.

Yours sincerely,
Charlene JY Liew

REFERENCES